300 related articles for article (PubMed ID: 17905106)
1. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
2. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Sartor AO; Tangen CM; Hussain MH; Eisenberger MA; Parab M; Fontana JA; Chapman RA; Mills GM; Raghavan D; Crawford ED;
Cancer; 2008 Jun; 112(11):2393-400. PubMed ID: 18383517
[TBL] [Abstract][Full Text] [Related]
3. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC; Kynaston H; Cook AD; Clarke NW; Catton CN; Cross WR; Petersen PM; Persad RA; Pugh CA; Saad F; Logue J; Payne H; Bower LC; Brawley C; Rauchenberger M; Barkati M; Bottomley DM; Brasso K; Chung HT; Chung PWM; Conroy R; Falconer A; Ford V; Goh CL; Heath CM; James ND; Kim-Sing C; Kodavatiganti R; Malone SC; Morris SL; Nabid A; Ong AD; Raman R; Rodda S; Wells P; Worlding J; Parulekar WR; Parmar MKB; Sydes MR;
Lancet; 2024 Jun; 403(10442):2416-2425. PubMed ID: 38763153
[TBL] [Abstract][Full Text] [Related]
4. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.
Parker CC; Clarke NW; Cook AD; Kynaston H; Catton CN; Cross WR; Petersen PM; Persad RA; Saad F; Bower LC; Logue J; Payne H; Forcat S; Goldstein C; Murphy C; Anderson J; Barkati M; Bottomley DM; Branagan J; Choudhury A; Chung PWM; Cogley L; Goh CL; Hoskin P; Khoo V; Malone SC; Masters L; Morris SL; Nabid A; Ong AD; Raman R; Tarver KL; Tree AC; Worlding J; Wylie JP; Zarkar AM; Parulekar WR; Parmar MKB; Sydes MR;
Lancet; 2024 Jun; 403(10442):2405-2415. PubMed ID: 38763154
[TBL] [Abstract][Full Text] [Related]
5. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.
Keizman D; Huang P; Antonarakis ES; Sinibaldi V; Carducci MA; Denmeade S; Kim JJ; Walczak J; Eisenberger MA
Prostate; 2011 Nov; 71(15):1608-15. PubMed ID: 21432863
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.
Chen XQ; Huang Y; Li X; Zhang P; Huang R; Xia J; Chen N; Wei Q; Zhu YC; Yang YR; Zeng H
Asian J Androl; 2010 Sep; 12(5):718-27. PubMed ID: 20694018
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.
Kashiwabara T; Suda S
BMC Cancer; 2018 May; 18(1):619. PubMed ID: 29855278
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated radiation therapy combined with androgen deprivation therapy for high-risk localized prostate cancer.
Lee TH; Pyo H; Yoo GS; Jeon SS; Seo SI; Jeong BC; Jeon HG; Sung HH; Kang M; Song W; Chung JH; Bae BK; Park W
J Med Imaging Radiat Oncol; 2024 Apr; 68(3):333-341. PubMed ID: 38477380
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients.
Lin GW; Yao XD; Zhang SL; Dai B; Ma CG; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Qin XJ; Ye DW
Asian J Androl; 2009 Jul; 11(4):443-50. PubMed ID: 19182820
[TBL] [Abstract][Full Text] [Related]
10. A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.
Lee KC; Bradley DA; Hussain M; Meyer CR; Chenevert TL; Jacobson JA; Johnson TD; Galban CJ; Rehemtulla A; Pienta KJ; Ross BD
Neoplasia; 2007 Dec; 9(12):1003-11. PubMed ID: 18084607
[TBL] [Abstract][Full Text] [Related]
11. Intermittent androgen suppression for rising PSA level after radiotherapy.
Crook JM; O'Callaghan CJ; Duncan G; Dearnaley DP; Higano CS; Horwitz EM; Frymire E; Malone S; Chin J; Nabid A; Warde P; Corbett T; Angyalfi S; Goldenberg SL; Gospodarowicz MK; Saad F; Logue JP; Hall E; Schellhammer PF; Ding K; Klotz L
N Engl J Med; 2012 Sep; 367(10):895-903. PubMed ID: 22931259
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of nadir PSA value and time to nadir PSA in patients with metastatic castration-naive prostate cancer receiving first-line hormonotherapy.
İnci BK; Gürler F; Sütcüoğlu O; Baştuğ V; Yazıcı O; Üner A; Özet A; Özdemir N
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S845-S850. PubMed ID: 38102905
[TBL] [Abstract][Full Text] [Related]
13. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
Carter HB; Ferrucci L; Kettermann A; Landis P; Wright EJ; Epstein JI; Trock BJ; Metter EJ
J Natl Cancer Inst; 2006 Nov; 98(21):1521-7. PubMed ID: 17077354
[TBL] [Abstract][Full Text] [Related]
14. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.
Lin J; Zahurak M; Beer TM; Ryan CJ; Wilding G; Mathew P; Morris M; Callahan JA; Gordon G; Reich SD; Carducci MA; Antonarakis ES
Urol Oncol; 2013 Jul; 31(5):581-8. PubMed ID: 21816640
[TBL] [Abstract][Full Text] [Related]
15. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study.
Barrett T; Gill AB; Kataoka MY; Priest AN; Joubert I; McLean MA; Graves MJ; Stearn S; Lomas DJ; Griffiths JR; Neal D; Gnanapragasam VJ; Sala E
Magn Reson Med; 2012 Mar; 67(3):778-85. PubMed ID: 22135228
[TBL] [Abstract][Full Text] [Related]
16. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis.
Ma J; Li H; Giovannucci E; Mucci L; Qiu W; Nguyen PL; Gaziano JM; Pollak M; Stampfer MJ
Lancet Oncol; 2008 Nov; 9(11):1039-47. PubMed ID: 18835745
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Keizman D; Zahurak M; Sinibaldi V; Carducci M; Denmeade S; Drake C; Pili R; Antonarakis ES; Hudock S; Eisenberger M
Clin Cancer Res; 2010 Nov; 16(21):5269-76. PubMed ID: 20978144
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy.
Pendleton JM; Tan WW; Anai S; Chang M; Hou W; Shiverick KT; Rosser CJ
BMC Cancer; 2008 May; 8():132. PubMed ID: 18471323
[TBL] [Abstract][Full Text] [Related]
19. Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
Kamada S; Sakamoto S; Kinoshita R; Zhao X; Kamasako T; Yamase R; Junryo R; Saito S; Sangjon P; Takei A; Yamada Y; Goto Y; Imamura Y; Iguchi T; Mizokami A; Suzuki H; Akakura K; Ichikawa T
Prostate; 2024 May; 84(7):636-643. PubMed ID: 38413843
[TBL] [Abstract][Full Text] [Related]
20. Role of PSA Kinetics in Hormone-refractory Prostate Cancer.
Sabur V; Untan I; Tatlisen A
J Coll Physicians Surg Pak; 2021 Jun; 31(6):673-678. PubMed ID: 34102779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
